A retrospective, interventional study comparing treatment outcomes between ophthalmological practices and a specialized macula clinic in patients with neovascular age-related macular degeneration who received intravitreal anti-VEGF treatment using ranibizumab or aflibercept
Latest Information Update: 03 May 2021
At a glance
- Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms 2019-01265
- 03 May 2021 New trial record